CCPSC starts treatment with ZAP-X platform for brain tumour therapy
The ZAP-X system is claimed to deliver stereotactic radiosurgery with precision, minimising damage to healthy brain tissue.
The Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France, has initiated treatments with a non-invasive brain tumour therapy called the ZAP-X Gyroscopic Radiosurgery platform, manufactured by ZAP Surgical Systems.
This advanced treatment is being offered by CCPSC, which is part of the American Hospital of Paris.
The ZAP-X system is claimed to deliver stereotactic radiosurgery (SRS) with precision, concentrating radiation on the tumour target while minimising damage to healthy brain tissue.
By providing a painless and outpatient treatment option, SRS offers outcomes comparable to or better than traditional surgeries.
Moreover, ZAP-X eliminates the need for shielded radiation treatment rooms and the use of radioactive isotopes, reducing costs.
CCPSC radiation oncologist Dr Bacem Belghith said: “Because of the significant percentage of cancer patients who develop brain metastases, it was imperative we support our radiation oncology program with a dedicated SRS solution such as ZAP-X.”
The vault-free design of the ZAP-X platform eliminates the requirement for expensive shielded treatment rooms.
CCPSC radiation oncologist Dr Alain Allaw said: “As ZAP-X is designed specifically for cranial radiosurgery it allows us to treat the most challenging cases with confidence.
“And unlike multi-purpose radiotherapy devices, ZAP-X provides patients with potentially lower healthy brain exposure to radiation, and thus enables greater flexibility for our clinical team to treat recurring brain metastases patients.”